Biotech Values

[WorstLuck]

Ramps can definitely be finicky.

30 is better than 20, I agree. But 30 is what I would describe as the minimum for a good launch at this stage IMHO. Just on very oversimplified math, the 11 million sold in Q4 are due for a boost and the 15.4 sold in Q1 with limited access should be replicable in Q2 with new open commercial sales. That's 26.4 million in what should be a favorable Q (Q2/Q4), so rounding down to 25 million and still coming up short doesn't look good no matter what the reason is.

The target for sales should be 30-40 million whether they get there or not. 20 should be punished by the market, and would be. 40 would be nicely rewarded. Just my opinion.